FDA reviews HPV vaccine for older women

The FDA has promised a speedy review of Gardasil, the HPV vaccine, for women over 26 years old.

The designation means that the U.S. Food and Drug Administration is expected to make its decision on the marketing application within 6 months, rather than within the agency’s typical 10-month review period.

Nice. Because let’s not forget that 25% of women in the U.S. (yes, grown-ups too) have HPV. Now we just have to see if the FDA sticks to their schedule. Hopefully the “controversy” factor will be a bit less since this about adult women.